These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1015075)

  • 1. [Characteristics of the reactogenic and immunogenic properties of killed influence vaccine purified and concentrated by the method of adsorbed chromatography on silicate sorbents].
    Peradze TV; Fridman EA; Kolikov VM; Bichurina MA; Goriunova VV
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Sep; (9):18-22. PubMed ID: 1015075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics of the basic parameters of killed influenza vaccine purified and concentrated on sodium borsilicate glass].
    Sumarokov AA; Agafonov VI; Perepelkin VS; Nefedova LA; Salmin LV
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Sep; (9):22-7. PubMed ID: 797189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenic study of killed influenza vaccine purified and concentrated by a chromatographic method on silicate sorbents. I. The immunogenic properties of a vaccine from the A/Victoria/72 strain].
    Malafeeva LK; Fridman EA; Zheleznova NV; Polzik TP; Ivanov KG
    Tr Inst Im Pastera; 1976; 47():124-8. PubMed ID: 210537
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunogenic study of killed influenza vaccine purified and concentrated by a chromatographic method on silica sorbents. II. The immunogenic properties of a vaccine from the A/Scotland/74 strain].
    Polzik TP; Bichurina MA; Goriunova VV; Bokhnevich GM; Polianskaia NIu
    Tr Inst Im Pastera; 1976; 47():128-33. PubMed ID: 210538
    [No Abstract]   [Full Text] [Related]  

  • 5. [Secretory immunity in persons inoculated with killed influenza vaccine purified and concentrated on silicate sorbents].
    Bichurina MA
    Tr Inst Im Pastera; 1976; 47():134-40. PubMed ID: 210539
    [No Abstract]   [Full Text] [Related]  

  • 6. [Increase in the effectiveness of anti-influenza immunization by use of a combination of inactivated and live vaccine].
    Smorodintsev AA; Orlov VA; Ermolaeva OM; Zhilova GP
    Vopr Virusol; 1978; (5):602-7. PubMed ID: 735019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of inactivated influenza vaccine, purified by adsorption chromatography on porous glas.
    Bresler S; Kolikov V; Katushkina N; Molodkin V; Friedman E; Zheleznova H; Malafeieva L; Peradze T; Beljakov V; Ivanov K
    Med Biol; 1975 Dec; 53(6):456-61. PubMed ID: 1214539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial.
    Arnou R; Eavis P; Pardo JR; Ambrozaitis A; Kazek MP; Weber F
    Hum Vaccin; 2010 Apr; 6(4):346-54. PubMed ID: 20372053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization.
    Phillips CA; Forsyth BR; Christmas WA; Gump DW; Whorton EB; Rogers I; Rudin A
    J Infect Dis; 1970; 122(1):26-32. PubMed ID: 5433710
    [No Abstract]   [Full Text] [Related]  

  • 10. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation data from experimental series on a killed influenza vaccine purified and concentrated by differential and density gradient centrifugation. II. The results of a study of the reactogenic properties of the vaccine].
    Karpukhin GI; Popov IV; Malikova EV
    Tr Inst Im Pastera; 1976; 47():156-9. PubMed ID: 802567
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.
    Subbotina TI; Tenkova TV; Sidorova LV; Shpilyuk GF; Drinevsky VP; Voitsekhovskaya EM; Konstantinov VK; Sominina AA
    Acta Virol; 1988 Nov; 32(6):494-502. PubMed ID: 2906221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
    Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.
    Clark A; Potter CW; Jennings R; Nicholl JP; Langrick AF; Schild GC; Wood JM; Tyrrell DA
    J Hyg (Lond); 1983 Jun; 90(3):351-9. PubMed ID: 6863909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
    N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics of the immunological and protective effect in the simultaneous and separate use of live and killed influenza vaccines].
    Orlov VA; Zhilova GP; Smorodintsev AA; Kozhukhov VM; Ignat'eva GS
    Vopr Virusol; 1985; 30(3):280-5. PubMed ID: 4049837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.